PFS
Fig. 3 · Panel A
Panel A 是同一 Fig. 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Tianshi Lu, Habib Hamidi, Mark A Socinski, Martin Reck, Federico Cappuzzo, Fabrice Barlesi, Robert M Jotte, Sören Müller, Aditi Qamra, Assaf Amitai, Xiangnan Guan, Eloisa Fuentes, Hartmut Koeppen, Jennifer M Giltnane, David S Shames, Marcus Ballinger, Meng Xiao He, Yulei Wang, Minu K Srivastava, Barzin Y Nabet
Nat Commun 17(1) 122
The phase 3 IMpower150 trial in treatment-naïve patients with metastatic non-small-cell lung cancer (NSCLC) demonstrates significantly longer progression-free (PFS) and overall survival (OS) with first-line atezolizumab (anti-PD-L1)-bevacizumab (anti-VEGF)-carboplatin-paclitaxel (ABCP) than with bevacizumab-carboplatin-paclitaxel (BCP). We characterise four molecular NSCLC subtypes identified by unsupervised clustering of transcriptomes of 564 pre-treatment primary tumour samples from IMpower150 using non-negative matrix factorization (NMF1-4). Each subtype has distinct tumour PD-L1 expression levels, epithelial characteristics, immune composition, and treatment outcomes. Both NMF2 (enriched in tumour proliferation signal, macrophages, and monocytes) and NMF4 (enriched in B cells and T cells) have elevated tumour PD-L1 expression. Of these two, only NMF4 demonstrates PFS and OS benefits with ABCP versus either BCP or atezolizumab-carboplatin-paclitaxel (ACP). Patients with NMF1 (enriched in basal and squamous-like cells) have improved outcomes on ABCP compared with ACP or BCP; those with NMF3 (enriched in adenocarcinoma signatures) show similar outcomes among treatments. These insights could help inform individualised first-line treatment for metastatic NSCLC.
1 个 Figure · 11 个 KM 面板
Fig. 3. Association between clinical outcomes with atezolizumab-bevacizumab-chemotherapy combinations and NMF subtype in IMpower150. a PFS in each treatment arm by NMF subtype. The forest plot shows the PFS HRs for ABCP vs BCP for each subtype. b OS in each treatment arm by NMF subtype. The forest plot shows the OS HRs for ABCP vs BCP. c Comparison of PFS across NMF subtypes by treatment. d Comparison of PFS (top 3 panels) and OS (bottom 3 panels) with ABCP vs BCP in NMF2 and NMF4 subtypes by PD-L1 level: PD-L1–high (tumour proportion score ≥ 50% by SP263 IHC assay), PD-L1–low (1%-49%) and PD-L1–negative (< 1%). Data in the ACP arm were not substantially different from those in the BCP arm and are not shown in the graphs to aid visualization. e Results of the multivariate analysis evaluating the association between the outcomes (PFS: left panel, and OS: right panel) and multiple factors on the ABCP arm. These factors include NMF subtypes, PD-L1 levels, tumor mutation burden, STK11/KEAP1 mutational status, and smoking history. Source data are provided as a Source Data file. For the forest plots in a,b , e , each row represents a different predictor variable, with the point estimates and 95% CIs for the HRs displayed as squares and horizontal error bars, respectively. The vertical dashed line represents the line of no effect (HR = 1.0). Variables with confidence intervals that do not cross this line are considered statistically significant. For the survival analyses in a , b , e , the log-rank test was used to compare Kaplan-Meier survival curves. Cox proportional hazards regression models were used to generate hazard ratios and 95% confidence intervals. Multivariable Cox proportional hazards regression models were used to compare the interdependence of distinct biomarkers for prediction of OS benefit. ABCP atezolizumab plus bevacizumab plus carboplatin-paclitaxel, ACP atezolizumab plus carboplatin-paclitaxel, BCP bevacizumab plus carboplatin-paclitaxel, NE not estimable.
Fig. 3 · Panel A
Panel A 是同一 Fig. 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Fig. 3 · Panel B
Panel B 是同一 Fig. 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Fig. 3 · Panel C
Panel C 是同一 Fig. 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Fig. 3 · Panel C_4
Panel C_4 是同一 Fig. 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Fig. 3 · Panel C_5
Panel C_5 是同一 Fig. 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Fig. 3 · Panel D
Panel D 是同一 Fig. 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Fig. 3 · Panel D_7
Panel D_7 是同一 Fig. 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Fig. 3 · Panel D_8
Panel D_8 是同一 Fig. 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Fig. 3 · Panel D_9
Panel D_9 是同一 Fig. 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Fig. 3 · Panel D_10
Panel D_10 是同一 Fig. 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Fig. 3 · Panel D_11
Panel D_11 是同一 Fig. 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
这些图片未产生 KM 曲线结果,不在主页面重复展示。